AXL and prostate carcinoma: When Mer was reduced in prostate cancer via shRNA (Figures 5A, S9, and S10), or a Mer inhibitor was employed (Figures 5B and S11), mTORC2 signaling activated by GAS6 was decreased, which was not observed with reduced Tyro3 and Axl expression.